Signos, founded in 2018, is pioneering a new frontier in healthcare by providing a unique means to manage weight and metabolic health through an FDA-cleared platform. At the intersection of Health Care and Machine Learning, Signos leverages Dexcom's Stelo CGM technology and advanced AI to convert glucose data into actionable insights, aiming to improve employee health outcomes.
The platform offers tangible benefits for employers by enabling healthier workforce populations, reducing dependency on costly medications, and helping forecast benefit expenditures more accurately. This contributes to lower healthcare costs and enhanced employee wellness strategies.
The company’s recent $20.00M Series B funding round, led by notable investors such as GV, Samsung NEXT, Cheyenne Ventures, and Dexcom Ventures, marks a significant milestone, underscoring investor confidence in Signos' innovative approach and potential impact on the healthcare industry.
